Postpartum Hypertension Study

NOT_YET_RECRUITING

I'm interested ...!!

The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.

Conditions:

🦠 Postpartum Pregnancy-Induced Hypertension 🦠 Postpartum Preeclampsia 🦠 Pregnancy-Induced Hypertension in Postpartum 🦠 Hypertensive Emergency

🗓️ Study Start (Actual) August 2024

🗓️ Primary Completion (Estimated) 1 January 2025

✅ Study Completion (Estimated) 1 January 2026

👥 Enrollment (Estimated) 104

🔬 Study Type INTERVENTIONAL

📊 Phase PHASE4

Locations:

📍 New York, New York, United States

📋 Eligibility Criteria

Description

Inclusion criteria
* Patients admitted to labor and delivery (L\&D) with blood pressure (BP) in severe range, defined as a systolic ≥160 mm Hg and/or diastolic ≥110 mm Hg
* Postpartum, immediately to 6 weeks postpartum
* With a prior diagnosis of chronic hypertension (not on medication) or hypertensive disorder of pregnancy
Exclusion criteria
* They may not have previously had exposure to either study medication within the previous 24-hour period.
* Patients with a known atrial-ventricular heart block or moderate to severe bronchial asthma will be excluded, or other contraindication to receiving either study medication

Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)

Sexes Eligible for Study: FEMALE

Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted 18 November 2021
First Submitted that Met QC Criteria 18 November 2021
First Posted 1 December 2021

Study Record Updates